Stem definition | Drug id | CAS RN |
---|---|---|
1310 | 56-86-0 |
Dose | Unit | Route |
---|---|---|
1.50 | g | O |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 582.58 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
None | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Foetal growth restriction | 73.07 | 42.69 | 15 | 294 | 6552 | 46679201 |
Infantile apnoea | 50.92 | 42.69 | 8 | 301 | 768 | 46684985 |
Selective eating disorder | 44.44 | 42.69 | 8 | 301 | 1737 | 46684016 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|
Source | Code | Description |
---|---|---|
ATC | A09AB01 | ALIMENTARY TRACT AND METABOLISM DIGESTIVES, INCL. ENZYMES DIGESTIVES, INCL. ENZYMES Acid preparations |
CHEBI has role | CHEBI:78675 | essential metabolite |
CHEBI has role | CHEBI:25512 | neurotransmitters |
CHEBI has role | CHEBI:27027 | trace elements |
CHEBI has role | CHEBI:50733 | nutritional supplement |
CHEBI has role | CHEBI:75771 | mus musculus metabolite |
CHEBI has role | CHEBI:76971 | e.coli metabolites |
CHEBI has role | CHEBI:173085 | ferroptosis inducers |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Classical phenylketonuria | contraindication | 7573000 | |
Poisoning by digitalis glycoside | contraindication | 12876009 | |
Sarcoidosis | contraindication | 31541009 | DOID:11335 |
Dehydration | contraindication | 34095006 | |
End stage renal disease | contraindication | 46177005 | DOID:784 |
Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
Heart disease | contraindication | 56265001 | DOID:114 |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Hyperparathyroidism | contraindication | 66999008 | DOID:13543 |
Ventricular fibrillation | contraindication | 71908006 | |
Hypercalciuria | contraindication | 71938000 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Kidney stone | contraindication | 95570007 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.97 | acidic |
pKa2 | 3.6 | acidic |
pKa3 | 10.35 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Metabotropic glutamate receptor 8 | GPCR | AGONIST | IC50 | 5.70 | IUPHAR | ||||
Metabotropic glutamate receptor 3 | GPCR | AGONIST | Ki | 7.40 | IUPHAR | ||||
Glutamate dehydrogenase 2, mitochondrial | Enzyme | WOMBAT-PK | |||||||
Glutamate dehydrogenase 1, mitochondrial | Enzyme | WOMBAT-PK | |||||||
Glutamate receptor ionotropic, kainate 4 | Ion channel | Ki | 7.74 | PDSP | |||||
Glutamate receptor 3 | Ion channel | Ki | 6.60 | PDSP | |||||
Metabotropic glutamate receptor 7 | GPCR | EC50 | 5.93 | CHEMBL | |||||
Excitatory amino acid transporter 3 | Transporter | Ki | 7.29 | CHEMBL | |||||
Adenosine receptor A3 | GPCR | IC50 | 6.21 | CHEMBL | |||||
Metabotropic glutamate receptor 1 | GPCR | Ki | 6.60 | CHEMBL | |||||
Metabotropic glutamate receptor 2 | GPCR | EC50 | 6.54 | CHEMBL | |||||
Metabotropic glutamate receptor 5 | GPCR | Ki | 6.41 | CHEMBL | |||||
Glutamate receptor ionotropic, kainate 1 | Ion channel | Ki | 6.15 | CHEMBL | |||||
Glutamate receptor ionotropic, kainate 5 | Ion channel | Ki | 6.15 | CHEMBL | |||||
Glutamate receptor ionotropic, kainate 3 | Ion channel | Ki | 6.10 | CHEMBL | |||||
Glutamate receptor 4 | Ion channel | Ki | 6.06 | CHEMBL | |||||
Glutamate receptor 2 | Ion channel | Ki | 6.03 | CHEMBL | |||||
Glutamate receptor ionotropic, kainate 2 | Ion channel | Ki | 5.96 | CHEMBL | |||||
Glutamate receptor 1 | Ion channel | Ki | 5.87 | CHEMBL | |||||
Metabotropic glutamate receptor 4 | GPCR | Ki | 5.85 | CHEMBL | |||||
Metabotropic glutamate receptor 6 | GPCR | EC50 | 5.31 | CHEMBL | |||||
Excitatory amino acid transporter 1 | Transporter | Ki | 4.46 | CHEMBL | |||||
Glutathione reductase, mitochondrial | Enzyme | Ki | 4.37 | CHEMBL | |||||
Excitatory amino acid transporter 2 | Transporter | Ki | 4.21 | CHEMBL | |||||
Glutamate receptor 1 | Ion channel | EC50 | 4.46 | CHEMBL | |||||
Glutamate receptor 2 | Ion channel | Ki | 6.55 | CHEMBL | |||||
Glutamate receptor 3 | Ion channel | EC50 | 4 | CHEMBL | |||||
Glutamate receptor 4 | Ion channel | EC50 | 4.77 | CHEMBL | |||||
Glutamate receptor ionotropic, kainate 1 | Ion channel | Ki | 6.85 | CHEMBL | |||||
Metabotropic glutamate receptor 1 | Unclassified | EC50 | 5 | CHEMBL | |||||
Metabotropic glutamate receptor 2 | Unclassified | EC50 | 5.40 | CHEMBL | |||||
Metabotropic glutamate receptor 3 | Unclassified | EC50 | 5.52 | CHEMBL | |||||
Metabotropic glutamate receptor 4 | GPCR | EC50 | 4.92 | CHEMBL | |||||
Metabotropic glutamate receptor 5 | Unclassified | EC50 | 5.36 | CHEMBL | |||||
Metabotropic glutamate receptor 6 | GPCR | EC50 | 4.80 | CHEMBL | |||||
Glutamate receptor ionotropic, NMDA 1 | Ion channel | EC50 | 5.54 | CHEMBL | |||||
Glutamate receptor ionotropic, kainate 2 | Ion channel | Ki | 5.48 | CHEMBL | |||||
Glutamate receptor ionotropic, kainate 3 | Ion channel | Ki | 6.31 | CHEMBL | |||||
Metabotropic glutamate receptor 8 | Unclassified | EC50 | 7.66 | CHEMBL | |||||
Metabotropic glutamate receptor 8 | Unclassified | Ki | 5.47 | CHEMBL | |||||
Glutamate racemase | Unclassified | Ki | 4.55 | CHEMBL | |||||
Glutamate racemase | Unclassified | Ki | 5.24 | CHEMBL |
ID | Source |
---|---|
D00007 | KEGG_DRUG |
138-15-8 | SECONDARY_CAS_RN |
4018681 | VANDF |
C0220839 | UMLSCUI |
CHEBI:29987 | CHEBI |
GLU | PDB_CHEM_ID |
CHEMBL76232 | ChEMBL_ID |
CHEMBL575060 | ChEMBL_ID |
CHEMBL1255943 | ChEMBL_ID |
DB00142 | DRUGBANK_ID |
D018698 | MESH_DESCRIPTOR_UI |
1369 | IUPHAR_LIGAND_ID |
66 | INN_ID |
3KX376GY7L | UNII |
611 | PUBCHEM_CID |
25916 | RXNORM |
4788 | MMSL |
4823 | MMSL |
7086 | MMSL |
NOCODE | MMSL |
d00487 | MMSL |
001113 | NDDF |
008075 | NDDF |
010581 | NDDF |
38909000 | SNOMEDCT_US |
42271003 | SNOMEDCT_US |
85214009 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.50 g | INTRAVENOUS | NDA | 23 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-3200 | SOLUTION | 749 mg | INTRAVENOUS | ANDA | 20 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-3205 | SOLUTION | 749 mg | INTRAVENOUS | ANDA | 20 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-4500 | SOLUTION | 749 mg | INTRAVENOUS | ANDA | 20 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-9341 | SOLUTION | 0.50 g | INTRAVENOUS | NDA | 23 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-9361 | SOLUTION | 0.30 g | INTRAVENOUS | NDA | 23 sections |
ProSol | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0338-0499 | INJECTION, SOLUTION | 1.02 g | INTRAVENOUS | NDA | 21 sections |
Clinisol | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0338-0502 | INJECTION, SOLUTION | 749 mg | INTRAVENOUS | ANDA | 18 sections |
Aminosyn-PF | HUMAN PRESCRIPTION DRUG LABEL | 18 | 0409-4178 | INJECTION, SOLUTION | 576 mg | INTRAVENOUS | NDA | 14 sections |
Aminosyn II | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0409-7171 | INJECTION, SOLUTION | 1107 mg | INTRAVENOUS | NDA | 19 sections |
Aminosyn II | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0409-7172 | INJECTION, SOLUTION | 738 mg | INTRAVENOUS | NDA | 19 sections |
Aminosyn-PF | HUMAN PRESCRIPTION DRUG LABEL | 18 | 0990-4179 | INJECTION, SOLUTION | 820 mg | INTRAVENOUS | NDA | 14 sections |
Aminosyn II | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0990-7171 | INJECTION, SOLUTION | 1107 mg | INTRAVENOUS | NDA | 19 sections |
Aminosyn II | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0990-7172 | INJECTION, SOLUTION | 738 mg | INTRAVENOUS | NDA | 19 sections |
Kabiven | HUMAN PRESCRIPTION DRUG LABEL | 24 | 63323-712 | INJECTION, EMULSION | 164 mg | INTRAVENOUS | NDA | 25 sections |
Perikabiven | HUMAN PRESCRIPTION DRUG LABEL | 24 | 63323-714 | INJECTION, EMULSION | 116 mg | INTRAVENOUS | NDA | 25 sections |
Women Secret Care | HUMAN OTC DRUG LABEL | 2 | 72530-102 | GEL | 1.74 g | TOPICAL | unapproved drug other | 8 sections |